biOasis Technologies Ord Shs BIOAF

Primary Symbol: V.BTI.H

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > $5.25 million

<< Previous

Bullboard Posts

Next >>

Post by prophetoffactzon Feb 28, 2023 8:04am

896 Views

Post# 35309006

$5.25 million

BTI received $5.25 million upfront for 4 LSDs.

If there is a way out of BTI's predicament that doesn't issue shares what could it look like?

If BTI sold 4 LSDs to Chiesi and XOMA for $5.25 million upfront what could BTI sell the remaining value of the Chiesi deal back to Chiesi for and how much upfront could BTI receive for selling Chiesi 100% control of the remmaining LSD opportunities(eg. Hunter, Gauchers)?

What could BTI receive upfront from J&J for 100% ownership for its multi-product xB3 applications? Or upfront from XOMA?

100% to Neuramedy?

100% Herceptin?

<< Previous

Bullboard Posts

Next >>

Visionstate set to leverage success in the U.S. market